| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(5 years from now) | |
| US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(5 years from now) | |
| US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(6 years from now) | |
| US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(6 years from now) | |
| US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(6 years from now) | |
| US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(6 years from now) | |
| US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(6 years from now) | |
| US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) | |
| US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) | |
Zyclara is owned by Bausch.
Zyclara contains Imiquimod.
Zyclara has a total of 9 drug patents out of which 0 drug patents have expired.
Zyclara was authorised for market use on 25 March, 2010.
Zyclara is available in cream;topical dosage forms.
Zyclara can be used as treatment of actinic keratosis, treatment of genital warts; treatment of perianal warts, treatment of perianal warts; treatment of genital warts.
The generics of Zyclara are possible to be released after 30 April, 2030.
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 25 March, 2010
Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis
Dosage: CREAM;TOPICAL
ZYCLARA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic